One stock that might be an intriguing choice for investors right now is Apellis Pharmaceuticals, Inc. (APLS) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably ...

Apellis Pharmaceuticals (APLS) reported net product sales of approximately $138 million in the United States for the fourth quarter of 2023, up significantly year over year. The company generates product revenues from the sale of its two marketed drugs, Empaveli (pegcetacoplan) and Syfovre (pegcetacoplan injection). Its top line also comprises of licensing and other revenues.The 39% sequential increase in product revenues (from $99.2 million) was driven by strong Syfovre sales. Syfovre recorded sales of $11 ...

Apellis Pharmaceuticals, Inc. (APLS) shares ended the last trading session 14.7% higher at $68.35. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5% loss over the past four weeks.The sudden rise in the stock price can be attributed to the strong preliminary net product revenues reported in the United States for the fourth quarter and full year 2023. Apellis' marketed portfolio of drugs comprise Empaveli (pegcetaco ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Founder and CEO Tim Sullivan - CFO Adam Townsend - CCO Caroline Baumal - CMO Meredith Kaya - SVP, IR Conference Call Participants Jonathan Miller - Evercore Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Derek Archila - Wells Fargo Eliana Merle - UBS Akash Tewari - Jeffer ...

Third Quarter 2023 Financial Results Conference Call Apellis Participants CEDRI C F RANCO I S, M. D. , Ph . D. Co-Founder, President & Chief Executive Officer AD AM TO W NS E ND ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or othe ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2023 Earnings Conference Call July 31, 2023 8:30 AM ET Company Participants Dr. Cedric Francois - Co-Founder and CEO Tim Sullivan - CFO Adam Townsend - CCO Dr. Caroline Baumal - CMO Meredith Kaya - SVP, IR Conference Call Participants Jonathan Miller - Evercore ISI Tazeen Ahmad - Bank of America Anupam Rama - JPMorgan Colleen Kusy - Robert W. Baird Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Justin Kim - Oppenheimer & C ...

SYFOVRE Safety and Usage - Over 68,000 vials of SYFOVRE have been distributed since launch[6] - There have been seven confirmed reports of retinal vasculitis (RV) in the real world, and one additional reported event is being evaluated[6] - Market research indicates that 13 retina specialists surveyed plan to continue using SYFOVRE as they had been prior to the vasculitis events[9] - Manufacturing processes and drug product quality assessments found no single manufacturing lot implicated, no manufacturing issues impacting product quality, no quality issues, and no contaminants discovered[8] Financial Performance - Apellis' cash of $616 million as of June 30, 2023, combined with expected revenues and Sobi reimbursements, is expected to fund operations into Q1 2025[13] - EMPAVELI U S Net Product Sales were $22.3 million in 2023, compared to $15.7 million in 2022[14] - SYFOVRE U S Net Product Sales reached $67.3 million[14] - Total revenue was $95.0 million, compared to $16.3 million in 2022[14] - Net loss was $(122.0) million, compared to $(156.0) million in 2022[14] Clinical Trial Data - SYFOVRE continues to show increasing effects over time in the GALE long-term extension study[15]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38276 APELLIS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-1537290 (State or other jur ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations and Strategic Finance Dr. Cedric Francois - Co-Founder and CEO Adam Townsend - Chief Commercial Officer Dr. Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Jon Miller - Evercore Tazeen Ahmad - BofA Anupam Rama - JPMorgan Colleen Kusy - Baird Yig ...